Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups

Braibant, Martinea; Gong, Eun-Yeunga,*; Plantier, Jean-Christophec; Moreau, Thierryd; Alessandri, Elodiec; Simon, Françoise; Barin, Francisa,b

AIDS:
doi: 10.1097/QAD.0b013e32835ecb42
Basic Science: Concise Communication
Abstract

Objective: HIV-1 has been classified into four groups: M, N, O and P. The aim of this study was to revisit the cross-group neutralization using a highly diverse panel of primary isolates.

Design: The panel of viruses included nine HIV-1 group O primary isolates, one recombinant M/O primary isolate, one group N primary isolates, one group P primary isolate, two group M (subtype B) primary isolates and the HIV-1 group M adapted strain MN.

Methods: All the viruses were tested for neutralization in TZM-bl cells, using sera issued from patients infected by viruses of group M (n = 11), O (n = 12) and P (n = 1), and a panel of nine human monoclonal broadly neutralizing antibodies (HuMo bNAbs).

Results: Although the primary isolates displayed a wide spectrum of sensitivity to neutralization by the human sera, cross-group neutralization was clearly observed. In contrast, the bNAbs did not show any cross-group neutralization, except PG9 and PG16. Interestingly, the group N prototype strain YBF30 was highly sensitive to neutralization by PG9 (IC50: 0.28 μg/ml) and PG16 (IC50: < 0.12 μg/ml). The interaction between PG9 and key residues of YBF30 was confirmed by molecular modeling.

Conclusion: The conservation of the PG9 and PG16 epitopes within groups M and N provides an argument for their relevance as components of a potentially efficient HIV vaccine immunogen.

Author Information

aUniversité François-Rabelais - Inserm U966

bLaboratoire de Bactériologie-Virologie, CHU Bretonneau, Tours

cUniversité de Rouen and CHU Charles Nicolle, Rouen

dUniversité François Rabelais - Inserm U1100, Tours

eLaboratoire de Virologie, Hôpital Saint-Louis, Paris, France.

*Present address: The Beatson Institute for Cancer Research, Switchback Road, Bearsden, G61 1BD, Glasgow, UK.

Correspondence to Dr Francis Barin, Laboratoire de Virologie, CHU Bretonneau, 37044, Tours Cedex, France. Tel: +33 2 4747 8058; fax: +33 2 4747 3610; e-mail: fbarin@med.univ-tours.fr

Received 3 November, 2012

Revised 17 December, 2012

Accepted 9 January, 2013

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).

© 2013 Lippincott Williams & Wilkins, Inc.